HUTCHMED Announces Changes to Board of Directors and Technical Committee
13 Julho 2023 - 5:30AM
HUTCHMED (China) Limited (“HUTCHMED” or the “Company”)
(Nasdaq/AIM:HCM, HKEX:13) today announces that with effect from
July 13, 2023:
(i) Mr Lefei
Sun, having left his position at General Atlantic, has resigned as
Non-executive Director and member of the Technical Committee of
HUTCHMED; and
(ii) Ms Ling
Yang, managing director of The Carlyle Group and co-head of Carlyle
Asia Healthcare, has been appointed as Non-executive Director of
HUTCHMED and will hold office until the next general meeting when
she will stand for re-election.
The Board of Directors of HUTCHMED (the “Board”)
is of the view that the appointment of Ms Yang would provide
significant benefits to HUTCHMED taking into consideration her
experience in biotechnology company management, business strategy,
capital markets and mergers and acquisitions. Ms Yang had been the
managing director of Carlyle and co-head of Carlyle Asia Healthcare
since November 2021, in charge of advising in healthcare investment
and portfolio activities of Carlyle in China. Carlyle owns
approximately 4.7% of the ordinary shares of HUTCHMED, through its
affiliate CA Fern Parent.
Mr Simon To, Chairman of HUTCHMED, said: “On
behalf of the Board, we would like to express our gratitude and
appreciation to Mr Lefei Sun for his contributions to the Company
and we wish him all the best for his future endeavors. We welcome
Ms Ling Yang to the Company. We believe that her expertise in life
sciences and healthcare investment would strengthen our Board as it
works towards achieving its goals.”
Ms Yang, aged 43, is chairwoman and
non-executive director of ADICON Holdings Limited; director of
Shenzhen Salubris Pharmaceuticals Co., Ltd.; non-executive director
of Ambio Pharmaceuticals and Ambio, Inc.; chairwoman of Adicon
(Hangzhou) Clinical Laboratories Co., Ltd. and Aidiken (Hangzhou)
Biotech Co., Ltd; and director of Adicon International Limited and
Manson Grand International Limited. She was previously
non-executive director of Ambio Holdings, Inc. Ms Yang previously
worked at KKR Asia Limited at which her last position was a
principal primarily responsible for carrying out investments made
by KKR Asia Limited. She also worked as an associate in the U.S.
leveraged buyout healthcare group of Carlyle; and as an analyst in
the investment banking division of The Goldman Sachs Group, Inc.
She graduated summa cum laude and is a member of Phi Beta Kappa
with a bachelor’s degrees in economics and computer science from
Smith College and she received her Master of Business
Administration degree from Harvard Business School.
Under the terms of her appointment, Ms Yang will
serve as a Non-executive Director of the Company until the next
general meeting. As a Non-executive Director, she will not receive
any fees for her service and that her appointment will be renewed
for successive 12-month periods, unless she is not re-elected at
the next general meeting or her appointment is otherwise terminated
earlier by either party in writing.
Save for the appointment listed above, Ms Yang
has held no other directorships or partnerships during the period
of five years prior to her appointment as a director of HUTCHMED.
Save for her role with Carlyle, she does not have any relationship
with any Directors, senior management or substantial or controlling
shareholders of HUTCHMED. Ms Yang does not have any interest in the
ordinary shares of HUTCHMED within the meaning of Part XV of the
Securities and Futures Ordinance (Cap.571 of the Laws of Hong
Kong).
Save for the information disclosed above, there
is no other information in relation to Ms Yang that is required to
be disclosed pursuant to Rule 17 and Schedule 2(g) of the AІM Rules
for Companies or Rule 13.51(2) of the Rules Governing the Listing
of Securities on The Stock Exchange of Hong Kong Limited (“HK
Listing Rules”) and there are no other matters concerning the
appointment of Ms Yang that are required to be brought to the
attention of the shareholders of HUTCHMED.
Pursuant to the requirements of Rule 13.51(2) of
the HK Listing Rules, Mr Sun has confirmed that he has no
disagreement with the Board and that there are no other matters
that need to be brought to the attention of the shareholders of the
Company in connection with his resignation from the Board.
Appointment of Special Advisor to the
Technical Committee
With respect to the announcements made on May
10, 2023 and May 12, 2023 on changes in board positions and
committee membership of the Company, the Board had decided to
appoint Professor Solange Peters as Special Advisor to the
Technical Committee of the Company with effect from July 12, 2023.
This decision follows further consideration by the Board and
discussions with Professor Peters. Professor Peters will not join
the Board.
Taking into account the expertise and reputation
of Professor Peters in biopharmaceutical research in oncology and
in immunology, the Board is of the view that her appointment as
Special Advisor to the Technical Committee (instead of the position
of an Independent Non-executive Director, as previously proposed)
would enable Professor Peters to contribute most effectively to the
scientific research and strategy of HUTCHMED.
Mr Simon To, Chairman of HUTCHMED, said: “The
Board warmly welcomes the appointment of Professor Peters as
Special Advisor to the Technical Committee, and looks forward to
working with her. We believe that her extensive experience in
oncology and immunology would be of immense value to the Company as
it develops drugs for the treatment of diseases in these
fields.”
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an
innovative, commercial-stage, biopharmaceutical company. It is
committed to the discovery and global development and
commercialization of targeted therapies and immunotherapies for the
treatment of cancer and immunological diseases. It has
approximately 5,000 personnel across all its companies, at the
center of which is a team of about 1,800 in oncology/immunology.
Since inception it has focused on bringing cancer drug candidates
from in-house discovery to patients around the world, with its
first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch-med.com or follow us on
LinkedIn.
Forward-Looking Statements
This announcement contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect HUTCHMED’s current expectations
regarding future events. Forward-looking statements involve risks
and uncertainties. Such risks and uncertainties include, among
other things, the risk that current or future appointees to
HUTCHMED’s board of directors are not effective in their respective
positions, the difficulty in locating and recruiting suitable
candidates for its board of directors and the management
difficulties which may arise from changes in HUTCHMED’s board of
directors. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. For further discussion of these
and other risks, see HUTCHMED’s filings with the U.S. Securities
and Exchange Commission, on AІM and with The Stock Exchange of Hong
Kong Limited. HUTCHMED undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
Annie Cheng, Vice President |
+1 (973) 306-4490 |
|
|
Media Enquiries |
|
Americas – Brad Miles, Solebury Strategic
Communications |
+1 (917) 570 7340 (Mobile) /
bmiles@soleburystrat.com |
Europe – Ben Atwell / Alex Shaw,
FTI Consulting |
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile) /
HUTCHMED@fticonsulting.com |
Asia – Zhou Yi, Brunswick |
+852 9783 6894 (Mobile) /
HUTCHMED@brunswickgroup.com |
|
|
Nominated Advisor |
|
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure
Gordon |
+44 (20) 7886 2500 |
HUTCHMED China (NASDAQ:HCM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
HUTCHMED China (NASDAQ:HCM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024